Clinical Trial

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-16; most recent amendment 2025-12-16.
Status change: Not Yet Recruiting → Recruiting 2024-08-13
Trial Details
NCT Number NCT06512051
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment 248 participants
Start Date 2024-07-30
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-23